BioAge Labs, Inc.

NasdaqGS:BIOA Stock Report

Market Cap: US$1.1b

BioAge Labs Management

Management criteria checks 3/4

BioAge Labs' CEO is Kristen Fortney, appointed in Apr 2015, has a tenure of 11.25 years. total yearly compensation is $2.89M, comprised of 20.8% salary and 79.2% bonuses, including company stock and options. directly owns 2.2% of the company’s shares, worth $23.09M. The average tenure of the management team and the board of directors is 5.5 years and 2.4 years respectively.

Key information

Kristen Fortney

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage20.79%
CEO tenure11.3yrs
CEO ownership2.2%
Management average tenure5.5yrs
Board average tenure2.4yrs

Recent management updates

Recent updates

Seeking Alpha • Jun 24

BioAge Labs: Developing A 'Pipeline In A Pill'

Summary BioAge Labs is focused on developing BGE-102, a promising oral NLRP3 inhibitor targeting cardiometabolic diseases and inflammation-driven conditions. BGE-102's Phase 1 data showed rapid, profound reductions in hsCRP and consistent decreases in IL-6 and fibrinogen, supporting its multi-organ potential. BIOA is well-capitalized, ending Q1 with $390M cash and no long-term debt, funding operations through 2029 despite commercialization being years away. An analysis around BioAge Labs follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • May 12

Earnings Beat: BioAge Labs, Inc. (NASDAQ:BIOA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

A week ago, BioAge Labs, Inc. ( NASDAQ:BIOA ) came out with a strong set of first-quarter numbers that could...
Analysis Article • Jul 15

Is BioAge Labs (NASDAQ:BIOA) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Jan 13

Novartis And BioAge Team Up To Develop Aging Therapies And Boost Investor Potential

Summary BioAge Labs and Novartis have formed a strategic partnership to discover age-related therapies, providing BioAge with crucial validation and funding amid Azelaprag's clinical trial failure. Despite BioAge's clinical setback, its substantial cash position and Novartis deal offer potential for a strategic pivot towards neuroinflammation and age-related conditions. Novartis benefits from BioAge's longevity data, potentially enhancing its neuroscience pipeline and mitigating revenue risks from upcoming loss of exclusivity on key drugs. I rate Novartis as a "Buy" for long-term investors due to its financial stability and growth prospects, while BioAge remains a "Hold" pending strategic updates. Read the full article on Seeking Alpha
Seeking Alpha • Sep 30

BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival

Summary The biotech sector is reviving, with IPOs reappearing and BioAge Labs' weight loss drug, Azelaprag, showing market potential. Biotech stocks are volatile, facing challenges like regulatory hurdles and high borrowing costs, exacerbated by interest rate hikes. The Federal Reserve's rate cuts have improved borrowing conditions, leading to a surge in biotech IPOs and a 53% rise in biotech stocks since October 2023. BioAge Labs' IPO success, with a 30% stock surge and $198 million raised, exemplifies the biotech sector's recovery and investor optimism. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Kristen Fortney's remuneration changed compared to BioAge Labs's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$90m

Dec 31 2025US$3mUS$600k

-US$81m

Sep 30 2025n/an/a

-US$76m

Jun 30 2025n/an/a

-US$79m

Mar 31 2025n/an/a

-US$71m

Dec 31 2024US$12mUS$521k

-US$71m

Sep 30 2024n/an/a

-US$71m

Jun 30 2024n/an/a

-US$62m

Mar 31 2024n/an/a

-US$66m

Dec 31 2023US$1mUS$493k

-US$64m

Compensation vs Market: Kristen's total compensation ($USD2.89M) is about average for companies of similar size in the US market ($USD3.51M).

Compensation vs Earnings: Kristen's compensation has been consistent with company performance over the past year.

CEO

Kristen Fortney (42 yo)

11.3yrs
Tenure
US$2,886,590
Compensation

Dr. Kristen Fortney, Ph D., is Executive Officer of Retro Biosciences, Inc. Dr. Kristen Fortney is Member of Scientific Advisory Board of Humanity Inc. Dr. Fortney serves as Member of Advisory Board at Kno...

Leadership Team

NamePositionTenureCompensationOwnership
Kristen Fortney
Co-Founder11.3yrsUS$2.89m2.2%
$ 23.1m
Eric Morgen
Co-Founder11.5yrsUS$1.45m0.15%
$ 1.6m
Paul Rubin
Chief Medical Officer & Executive VP of Research6.2yrsUS$1.48mno data
Dov Goldstein
Chief Financial Officer4.7yrsno data0.082%
$ 864.3k
Shane Barton
Senior Vice President of Finance & Accountingno datano data0%
$ 0
Rusty Montgomery
Senior Vice President of Researchno datano datano data
Julie Gammelgard
Senior Vice President of People4.5yrsno datano data
Peng Leong
Chief Business Officer & Therapeutic Area Head of Brain Aging7.3yrsno datano data
BJ Sullivan
Chief Strategy Officer5.5yrsno datano data
Ann Neale
Chief Development Officer4.7yrsno datano data
Patrick Martin
Senior Vice President of Clinical Science4.5yrsno datano data
Sangita Ghosh
SVP of Technical Operationsno datano datano data
5.5yrs
Average Tenure
55yo
Average Age

Experienced Management: BIOA's management team is seasoned and experienced (5.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kristen Fortney
Co-Founder11.3yrsUS$2.89m2.2%
$ 23.1m
Eric Morgen
Co-Founder9.1yrsUS$1.45m0.15%
$ 1.6m
James Healy
Independent Director2.4yrsUS$137.75k0%
$ 0
Jean-Pierre Garnier
Independent Chairman of the Board1.9yrsUS$172.75k0%
$ 0
Patrick Gerald Enright
Independent Director2.4yrsUS$129.25k0%
$ 0
Vijay Pande
Independent Director9.1yrsUS$114.01kno data
Michael Davidson
Independent Director2.3yrsUS$138.75k0%
$ 0
G. Alexander Fleming
Member of Scientific & Metabolic Advisory Board2.2yrsno datano data
William Evans
Member of Scientific & Metabolic Advisory Board2.2yrsno datano data
Caroline Apovian
Member of Scientific & Metabolic Advisory Board2.2yrsno datano data
Rekha Hemrajani
Independent Director4.9yrsUS$141.75k0.0067%
$ 70.9k
Timothy Rolph
Member of Scientific & Metabolic Advisory Board2.2yrsno datano data
2.4yrs
Average Tenure
61yo
Average Age

Experienced Board: BIOA's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/09 21:31
End of Day Share Price 2026/07/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioAge Labs, Inc. is covered by 11 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas ShraderBTIG
Samantha Lynn SemenkowCitigroup Inc
Salveen RichterGoldman Sachs